Seattle Genetics, Takeda sales and marketing update

Takeda launched in Japan Adcetris brentuximab vedotin to treat patients with CD30-positive relapsed or refractory Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL). The determination of a price for Adcetris in Japan triggered a $9 million milestone payment to Seattle Genetics under a 2009 deal to co-develop the drug. Adcetris is administered as a 50 mg IV drip infusion, and the recommended dose in adults is 1.8 mg/kg of body weight every three weeks. The dose can be reduced based on symptoms of patients. Seattle Genetics deferred questions regarding pricing for Adcetris to Takeda, which could not be reached. ...